Free Research Report Download:
The Cancer Market Outlook To 2014
Free Pharmaceutical Market Research Reports
Biotechnology
Corporate & Fiscal
Drug Delivery
Health Products
Hospital Markets
Indication Areas
Medical Devices
Prescription Medicines
R&D
Custom Research
Pharmaceutical Events & Conferences
Contact
Terms & Conditions
Privacy
Home >
Asthma and COPD Market Forecast
Market Study
Published: June 2009
Pages: For full details, please email keithw@cmsinfo.com
Tables: For full details, please email keithw@cmsinfo.com
From: GBP 9500.00 Buy Now!
Research from: Datamonitor
Sector: Indication Areas
Introduction
Although the respiratory market has expanded considerably from 2004 to 2008, growth in the seven major markets is slowing down from 2009 to 2011, after which sales will decline due to patent expiries of leading brands. Growth is driven by the expansion of sales in existing classes, the launch of major new products with safety and convenience advantages, and the results of several landmark trials.
Reasons to Purchase
*Identify key opportunities and threats that will impact the use and uptake of new and existing products
*Quantify the future size and scope of the asthma/COPD market and predict the performance of key compounds
*Understand critical success factors in growing and defending respiratory brand franchises from new entrants and generics
Although the respiratory market has expanded considerably from 2004 to 2008, growth in the seven major markets is slowing down from 2009 to 2011, after which sales will decline due to patent expiries of leading brands. Growth is driven by the expansion of sales in existing classes, the launch of major new products with safety and convenience advantages, and the results of several landmark trials.
Reasons to Purchase
*Identify key opportunities and threats that will impact the use and uptake of new and existing products
*Quantify the future size and scope of the asthma/COPD market and predict the performance of key compounds
*Understand critical success factors in growing and defending respiratory brand franchises from new entrants and generics